Home
Mail
Search
News
Finance
Sport
Lifestyle
Celebrity
Movies
Weather
Mobile
More
Yahoo
Mail
Cryptocurrencies
News
Property
Money
Markets
Industries
Watchlists
My Portfolio
My Screeners
Singapore markets closed
Straits Times Index
3,297.55
-26.98
(-0.81%)
Nikkei
38,814.56
+94.09
(+0.24%)
Hang Seng
17,941.78
-170.85
(-0.94%)
FTSE 100
8,146.86
-16.81
(-0.21%)
Bitcoin USD
66,190.76
-41.39
(-0.06%)
CMC Crypto 200
1,374.20
-43.67
(-3.08%)
SciClone Pharmaceuticals (Holdings) Limited (6600.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
18.560
-0.020
(-0.11%)
At close: 04:08PM HKT
Summary
Chart
Statistics
Historical data
Profile
Financials
Analysis
Options
Holders
Sustainability
Show
:
Income statement
Balance sheet
Cash flow
Annual
Quarterly
Income statement
Currency in CNY.
All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
3,155,614
3,155,614
2,749,681
2,518,474
1,918,562
Cost of revenue
799,413
799,413
679,196
585,468
428,106
Gross profit
2,356,201
2,356,201
2,070,485
1,933,006
1,490,456
Operating expenses
Research development
170,679
170,679
123,860
134,389
75,420
Selling general and administrative
970,105
970,105
852,754
785,620
672,609
Total operating expenses
1,099,014
1,099,014
964,489
894,018
735,401
Operating income or loss
1,257,187
1,257,187
1,105,996
1,038,988
755,055
Interest expense
58,193
58,193
46,593
40,191
29,592
Income before tax
1,217,397
1,217,397
940,080
1,025,873
816,809
Income tax expense
95,495
95,495
84,725
102,512
63,114
Income from continuing operations
1,121,902
1,121,902
855,355
923,361
753,695
Net income
1,121,902
1,121,902
855,355
923,361
753,695
Net income available to common shareholders
1,121,902
1,121,902
855,355
923,361
753,695
Basic EPS
1.27
1.83
1.27
1.42
1.11
Diluted EPS
1.21
1.72
1.21
1.33
1.11
Basic average shares
673,221
614,710
673,221
651,801
677,874
Diluted average shares
708,140
650,433
708,140
695,359
677,874
Data disclaimer
Help
Suggestions
Terms
and
Privacy Policy
Privacy dashboard
About our ads
© 2024 Yahoo. All rights reserved.